Tokyo Tape
Sign in
← Hokuyaku Takeyama Holdings

Half-year report · Q2

3055.TEDINET S100UNC6
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥141.2bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥275.4bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥135.9bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥1.1bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥1.1bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥1.4bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥3.5bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.4bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥1.4bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥1.3bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥884m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.2bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥730m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥884m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥730m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥149.6bnat 2024-09-30Cons.Assets
Total assets¥147.3bnat 2024-03-31Cons.Assets
Total assets¥147.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥88.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥86.6bnat 2024-03-31Cons.Liabilities
Net assets / equity¥60.8bnat 2024-09-30Cons.Net assets
Net assets / equity¥60.7bnat 2024-03-31Cons.Net assets
Net assets / equity¥58.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.1bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥20.8bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥21.1bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥20.8bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥22.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.0bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥2.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥5.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥2.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥696m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥898m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥596m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥41.262024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥100.22023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥33.352023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio40.6%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio41.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio39.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 56
SegmentItemPeriodValue
Otherother segmentsrevenue2024-04-01 → 2024-09-30¥1.3bn
Otherother segmentsrevenue external2024-04-01 → 2024-09-30¥33m
Otherother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥1.2bn
Otherother segmentssegment profit2024-04-01 → 2024-09-30¥566m
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentrevenue2024-04-01 → 2024-09-30¥6.3bn
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentrevenue external2024-04-01 → 2024-09-30¥6.3bn
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥5m
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentsegment profit2024-04-01 → 2024-09-30−¥5m
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentrevenue2024-04-01 → 2024-09-30¥1.0bn
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentrevenue external2024-04-01 → 2024-09-30¥289m
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥712m
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentsegment profit2024-04-01 → 2024-09-30¥22m
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentrevenue2024-04-01 → 2024-09-30¥34.1bn
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentrevenue external2024-04-01 → 2024-09-30¥33.8bn
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥309m
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentsegment profit2024-04-01 → 2024-09-30¥407m
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentrevenue2024-04-01 → 2024-09-30¥2.1bn
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentrevenue external2024-04-01 → 2024-09-30¥2.1bn
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2m
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentsegment profit2024-04-01 → 2024-09-30¥142m
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentrevenue2024-04-01 → 2024-09-30¥102.8bn
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentrevenue external2024-04-01 → 2024-09-30¥98.6bn
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentsegment profit2024-04-01 → 2024-09-30¥750m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥147.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥141.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥1.9bn
Otherother segmentsrevenue2023-04-01 → 2023-09-30¥1.3bn
Otherother segmentsrevenue external2023-04-01 → 2023-09-30¥29m
Otherother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥1.3bn
Otherother segmentssegment profit2023-04-01 → 2023-09-30¥615m
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentrevenue2023-04-01 → 2023-09-30¥6.6bn
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentrevenue external2023-04-01 → 2023-09-30¥6.6bn
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥5m
jpcrp040300-q2r_E03003-000Dispensing Industryreportable segmentsegment profit2023-04-01 → 2023-09-30¥27m
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentrevenue2023-04-01 → 2023-09-30¥794m
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentrevenue external2023-04-01 → 2023-09-30¥263m
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥530m
jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segmentsegment profit2023-04-01 → 2023-09-30¥33m
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentrevenue2023-04-01 → 2023-09-30¥31.7bn
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentrevenue external2023-04-01 → 2023-09-30¥31.4bn
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥283m
jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segmentsegment profit2023-04-01 → 2023-09-30¥581m
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentrevenue2023-04-01 → 2023-09-30¥2.0bn
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.0bn
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E03003-000Nursing Industryreportable segmentsegment profit2023-04-01 → 2023-09-30¥106m
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentrevenue2023-04-01 → 2023-09-30¥100.0bn
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentrevenue external2023-04-01 → 2023-09-30¥95.5bn
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥4.5bn
jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segmentsegment profit2023-04-01 → 2023-09-30¥502m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥142.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥135.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥6.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 541
ItemContextValueUnit
Loss on sales of noncurrent assets elPrior1YTDDuration0JPY
Loss on sales of noncurrent assets elCurrentYTDDuration1000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration1000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration4000000JPY
Loss on valuation of investment securities elPrior1YTDDuration111000000JPY
Loss on valuation of investment securities elCurrentYTDDuration8000000JPY
Extraordinary lossPrior1YTDDuration112000000JPY
Extraordinary lossCurrentYTDDuration14000000JPY
Income before income taxesPrior1YTDDuration1308000000JPY
Income before income taxesCurrentYTDDuration1390000000JPY
Income taxes currentPrior1YTDDuration727000000JPY
Income taxes currentCurrentYTDDuration779000000JPY
Income taxes deferredPrior1YTDDuration-149000000JPY
Income taxes deferredCurrentYTDDuration-274000000JPY
Income taxesPrior1YTDDuration577000000JPY
Income taxesCurrentYTDDuration505000000JPY
Profit lossPrior1YTDDuration730000000JPY
Profit lossCurrentYTDDuration884000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration0JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration0JPY
Profit loss attributable to owners of parentPrior1YTDDuration730000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration884000000JPY
Profit lossPrior1YTDDuration730000000JPY
Profit lossCurrentYTDDuration884000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration1066000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-139000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration9000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-11000000JPY
Other comprehensive incomePrior1YTDDuration1076000000JPY
Other comprehensive incomeCurrentYTDDuration-151000000JPY
Comprehensive incomePrior1YTDDuration1807000000JPY
Comprehensive incomeCurrentYTDDuration733000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration1806000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration732000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration0JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration0JPY
Income before income taxesPrior1YTDDuration1308000000JPY
Income before income taxesCurrentYTDDuration1390000000JPY
Depreciation and amortization ope cfPrior1YTDDuration521000000JPY
Depreciation and amortization ope cfCurrentYTDDuration526000000JPY
Amortization of goodwill ope cfPrior1YTDDuration54000000JPY
Amortization of goodwill ope cfCurrentYTDDuration55000000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration-1000000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration110000000JPY
Interest and dividends income ope cfPrior1YTDDuration-164000000JPY
Interest and dividends income ope cfCurrentYTDDuration-179000000JPY
Interest expenses ope cfPrior1YTDDuration0JPY
Interest expenses ope cfCurrentYTDDuration0JPY
Equity in earnings losses of affiliates ope cfPrior1YTDDuration-67000000JPY
Equity in earnings losses of affiliates ope cfCurrentYTDDuration-55000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass